OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel
Authors' conclusion
The lack of change in patient's perceptions of the disease, treatment, and supportive care information provided over the first 6 months of LAN treatment may suggest that physicians provided adequate information at the treatment initiation.
Study context
- Population
- Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) initiating lanreotide autogel, 31 specialised centres in France93 completed ≥1 primary dimension
- Participants
- 115 patients
- Exposure
- 6 months vs baseline of lanreotide (LAN) treatment
- Outcome
- Absolute change in patient's perception of information (QLQ-INFO25 disease, treatment, supportive care dimensions)
- Follow-up
- Baseline to month 6
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Change in QLQ-INFO25 information dimension scores · baseline to 6 months
Each group vs baselineEstimate (98.34% CI)P value
Month 6
change (disease) −2.84(−8.69 to 3.01)
P = 0.24Month 6
change (treatment) −4.37(−11.26 to 2.52)
P = 0.13Month 6
change (supportive care) 0.46(−6.78 to 7.70)
P = 0.88Observational data: associations, not effects.
Further findings
| Outcome | Baseline |
|---|---|
| Baseline QLQ-INFO25 scores (maximum 100) | mean 63.41 (SD 20.71) |
| Dimension | disease |
- Baseline QLQ-INFO25 scores (maximum 100): Baseline mean 58.85 (SD 19.00) · dimension treatment
- Baseline QLQ-INFO25 scores (maximum 100): Baseline mean 26.53 (SD 24.69) · dimension supportive care
Health-related quality of life (HRQoL) · baseline to 6 months
- No significant change in HRQoL between baseline and 6 months
Original publication
OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel. Eur J Endocrinol. Published 5 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →